Ann: Interim data in Phase 2 study of SNT-5505 in myelofibrosis, page-9

They will eventually rinse through , SP still has upward momentum ,,,

Really thought the strategy from management would be to apply effort on the messaging front to muster up some market wide interest with the 2nd set of Phase II Data on the Horizon to build a decent value base to launch the data from to maximise SH value..

With this being the final Interim Data prior to the actual Phase II data announcement I can only hope they are keeping their powder dry for a monumental push with the Phase II..

Biotech Sector is now recovering ,,, SNT needs to remain in the lead group of the recovery or there is a risk that Capital will shift to those delivering higher returns..

still a long way off the 9c we had in February and volume is certainly lighter..

SNT 5505 again from the update has a terrific safety profile and delivering superior benefits to the current Standard of Care...
Increased PR and Company Awareness would certainly be of benefit..

Best of luck for the day ,, hopefully we break and settle above 6 today NZT